Big pharma Merck ( MRK) reported stellar results for its phase-two hepatitis C (HCV) drug trials Thursday, sparking debate among analysts over its potential to take market share from leader Gilead Sciences. At the International Liver Congress in London, Merck reported a 98% cure rate in patients with hepatitis…
Hepatitis C in the News Your source for hepatitis C-related news from around the web.
Not sure what to submit? Read our news guidelines first.
A normal side effect of treatment for Hepatitis C is concentration issues and short term memory lapse, better know as, Brain Fog. There are times when you feel like a fog has rolled in your brain making concentration difficult. It's temporary. It comes and goes, fades in and out.
Researchers at the Sahlgrenska Academy have identified a gene, which explains why certain patients with chronic hepatitis C do not experience relapse after treatment. The discovery may contribute to more effective treatment. More than 100 million humans around the world are infected with hepatitis C virus.
The number of Americans with hepatitis C fell 16 percent to 2.7 million over almost a decade, a government survey found, just as new, more effective treatments for the chronic liver disease reach the market. The survey by the Centers for Disease Control and Prevention covers data gathered from 200…
Hepatitis C is a disease that negatively impacts health through inflammation of the liver. The liver is the bodily organ that processes everything we put into our bodies, so it's vital we learn to keep it in the best condition possible, especially if it's struggling through hep C.
LONDON — An investigational drug combination cured almost all patients with the form of hepatitis C that is most common in North America, researchers said.
Hepatitis C is now considered a "curable" disease by doctors, thanks to two new drugs - Olysio, manufactured by Johnson & Johnson, and the recently released Sovaldi, a product of Gilead Sciences.
AbbVie's HCV Drug Cocktail Cures 99% in Trial Print this page AbbVie Inc. is one step closer to marketing its two-drug combination for the treatment of Hepatitis C. Bloomberg News AbbVie Hepatitis C Combo Cures Almost All Patients in Late Trial By Simeon Bennett March 03, 2014 AbbVie Inc.
— Many aren't aware they carry the liver-destroying virus, experts say.
The death from liver cancer of Lou Reed last October helped raise awareness of the devastating toll being taken by hepatitis C in the United States. Following is a guide to the evolution of the illness and its treatment. Although HCV now kills more Americans than HIV, the hepatitis…